KILL Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials

 

Aditxt, Inc. requests that their press release NewsItemId: 20250414955183 issued April 14, 2025 “Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials” be killed.

The release was issued in error by Aditxt, Inc.

A replacement release will not be issued at this time.

Contacts

Aditxt, Inc. 

Corporate Communications 

Jeff Ramson, PCG Advisory, Inc. 

T: 646-863-6893 

contactus@aditxt.com

More News

View More

Recent Quotes

View More
Symbol Price Change (%)
AMZN  209.92
+1.36 (0.65%)
AAPL  274.70
+2.56 (0.94%)
AMD  213.84
+0.00 (0.00%)
BAC  51.51
+1.10 (2.17%)
GOOG  311.24
+0.32 (0.10%)
META  651.10
+11.80 (1.85%)
MSFT  389.00
+0.00 (0.00%)
NVDA  197.21
+4.36 (2.26%)
ORCL  150.44
+4.30 (2.94%)
TSLA  416.09
+6.71 (1.64%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.